ArticleBMC infectious diseases2025
Effective sequential therapy of linezolid and contezolid against HA-MRSA-induced necrotizing pneumonia in a 95-year-old patient with multimorbidity.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDespite progress in new antibiotic development, active surveillance, and infection prevention, health care-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) remains a major pathogen; it continues to pose a high-risk threat, especially in extremely elderly patients with necrotizing pneumonia and multiorgan dysfunction on polypharmacy. Multimorbidity, immunosenescence, and frailty in the elderly increase the risk of adverse outcomes, severely restricting therapeutic options. CASE PRESENTATION: We present the case of a long-term hospitalized 95-year-old woman with multimorbidity and multiorgan dysfunction who developed hospital-acquired necrotizing pneumonia due to MRSA. The diagnosis was established through metagenomic next-generation sequencing, bacterial culture of bronchoalveolar lavage fluid (BALF), and imaging. Linezolid was initially incorporated into the antimicrobial treatment regimen. After three weeks, owing to the bone marrow suppression caused by linezolid, contezolid (400 mg PO every 12 h) was adopted as an alternative therapy; this led to a significant reduction in the size of the lung cavity. Considering the cost-effectiveness and persistent risk of Pseudomonas aeruginosa and Elisabethia pacificus infection, as evidenced by the BALF culture results obtained at that time, the treatment was subsequently adjusted to oral linezolid combined with intravenous levofloxacin to achieve better infection control.
conclusionsThis case demonstrates the effectiveness of a sequential approach with a linezolid‒contezolid strategy for treating HA-MRSA-induced necrotizing pneumonia, leading to the regression of cavitary lesions and significant clinical improvement in elderly patients with multimorbidity, highlighting the importance of individualized treatment strategies in managing complex infections in vulnerable patient populations and offering valuable insights for future clinical practice. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.